• A Medication Study for Those with Relapsing Forms of Multiple Sclerosis

    Official Title A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis.

    Purpose

    This study is being done to determine how effective an investigational new drug (Ublituximab) is when given to those who have multiple sclerosis and what side effects may happen. Ublituximab has not yet been approved by the United States Food and Drug Administration (FDA), and is for use in clinical trials for people with relapsing forms of multiple sclerosis. The purpose of this clinical trial is to determine what dose and effect the study drug, Ublituximab, has on Multiple Sclerosis (MS) and those who have MS.

    Could this study be right for you?

    • Ages 18-55
    • Diagnosis of Relapsing Multiple Sclerosis
    • 2 or more relapses in prior 2 years or 1 relapse in the year prior to screening
    • Active disease
    • Other eligibility criteria to be discussed during screening

    Age Range

    18 and up
  • Medication Study for those with Remitting Relapsing Multiple Sclerosis who have not responded to other Treatments (Ages 18-55)

    Official Title AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT

    Purpose

    The purpose of this study is to determine the effectiveness of the drug ocrelizumab in those with Remitting Relapsing Multiple Sclerosis who have not had good outcomes with other Disease-Modifying Treatment.

    Could this study be right for you?

    You may be eligible for this study if you:

    • are between the ages of 18 and 55 years
    • have a definite diagnosis of Relapsing Remitting MS
    • have a length of disease duration (from first symptom) of less than or equal to 8 years
    • have been treated with no more than 2 prior disease-modifying treatments (discontinued due to lack of efficiency)

    Age Range

    18 and up
  • Medication Study for those with Relapsing Remitting Multiple Sclerosis (Ages 18-65)

    Official Title A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis

    Purpose

    The purpose of this study is to evaluate the long-term safety and tolerability of a drug (ALKS 8700) used to treat adults with Relapsing Remitting Multiple Sclerosis.

    Could this study be right for you?

    You may be eligible for this study if you:

    • are between 18 and 65 years of age
    • have a confirmed diagnosis of Relapsing Remitting Multiple Sclerosis
    • EDSS score of 0.0-6.0 at screening and visit 2

    Age Range

    18 and up
  • Medication Study for those with Relapsing Multiple Sclerosis (Ages 18-55)

    Official Title AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

    Purpose

    The purpose of this study is to determine exactly how the drug Ocrelizumab interacts with human cells to produce its intended effect in those with Relapsing Multiple Sclerosis (RMS).

    Could this study be right for you?

    You may be eligible for this study if you:

    • Have been diagnosed with Relapsing Multiple Sclerosis
    • Have an EDSS score of 0-5.5, inclusive, at screening, and a disease duration less than 15 years if EDSS > 5.0
    • Are either treatment-naïve or receiving treatment with disease-modifying therapies
    • Have had at least one clinically documented relapse in the past year and/or at least one T1-weighted Gd-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment

    Age Range

    18 and up